1) Patients with biliary atresia: 21( male 5, female 16)
Median age at Kasai portoenterostomy; 56 days
2) Baby with abnormal liver function test or jaundice (control 1): 9 (male 7, female 2)
Median age at assignment; 72days
3) Healthy control (control 2): none
The enrollment was progressed as expected, but did not reach the target number due to some patients not wishing to participate in the study. In addition, as usual with biliary atresia, many patients discontinued the study due to liver transplantation or severe gastrointestinal bleeding.
Finally, 7 patients completed the 2-year study period, 9 required liver transplantation, 3 had gastrointestinal bleeding, and 2 had discontinued the study at the request of their parents.
For control group A, 9 subjects participated. For this group, only blood specimen was collected at the enrollment.
There is no TRD.
In the BA group, liver transplantation: 9 cases, gastrointestinal bleeding: 3 cases. These were evaluated due to the progression of BA and to be unrelated to clinical studies.
Nothing particular occurred on control group 1.
Primary endpoint: Liver fibrosis was evaluated with M2BPGi.
Though the number of cases was not large enough to evaluate a statistically significant difference, the median M2BPGi was 0.96 in 7 cases of EPA group, and the median M2BPGi was 2.29 in 11 patients of the non-EPA group. M2BPGi tended to be lower in the EPA group.
Secondary endpoints: No statistical difference was proven in preoperative eicosanoids between two groups.
Median M2BPGi of cases without jaundice 2 years after portoenterostomy with EPA supplement was lower than that of the cases without EPA supplement, though showing no statistically significant. This was considered due to the small number of cases.
There was no significant difference in eicosanoid measurements between BA patients and control 1.
Many cases were withdrawn due to worsening of the current disease. It is difficult to enroll the necessary cases for this study. This study was discontinued.
1) New case with biliary atresia. 2) As control group A, cases of suspected biliary atresia with liver dysfunction or jaundice. 3) As control group B, healthy individuals with similar age.
主たる除外基準 / Exclusion Criteria
研究開始1か月以内の輸血歴
A history of blood transfusion within 1 month before enrollment
年齢下限 / Age Minimum
下限なし
No limit
年齢上限 / Age Maximum
上限なし
No limit
性別 / Gender
男性・女性
Both
中止基準
1)肝移植の準備が必要な状態。2)大量出血
対象疾患名 / Health Condition(s) or Problem(s) Studied
胆道閉鎖症、新生児肝炎、アラジール症候群、PFICなど
biliary atresia, neonatal hepatitis, Alagille syndrome, PFIC, etc.
対象疾患コード / Code
対象疾患キーワード / Keyword
介入の有無
あり
介入の内容 / Intervention(s)
エイコサペンタエン酸を30(±10)mg/kg/day経口投与
oral administration of 30(+/- 10)mg/kg/day of eicosapentaenoic acid
介入コード / Code
介入キーワード /Keyword
主たる評価項目 / Primary Outcome(s)
BA患者の肝線維化は軽減されるか。
Liver fibrosis in BA patients with or without administration of EPA
副次的な評価項目 / Secondary Outcome(s)
BA患者と非BA患者では長鎖多価不飽和脂肪酸、エイコサノイドの濃度に差があるか。
The difference of concentration of long chain polyunsaturated fatty acids, or eicosanoids among BA group and non-BA groups